Oral Hypoglycemic Agents Market Report 2026

Oral Hypoglycemic Agents Market Overview

• Oral Hypoglycemic Agents market size has reached to $59.57 billion in 2025 • Expected to grow to $75.62 billion in 2030 at a compound annual growth rate (CAGR) of 4.9% • Growth Driver: Rising Prevalence Of Type 2 Diabetes Driving Growth In The Market Due To Increasing Obesity And Demand For Effective Blood Sugar Management • Market Trend: Pharma Innovators Boost R&D As Demand For Advanced Oral Antidiabetic Solutions Rises Worldwide • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oral Hypoglycemic Agents Market?

Oral hypoglycemic agents (OHAs) are medications taken by mouth to help lower blood glucose (sugar) levels in individuals with type 2 diabetes mellitus. These drugs work through various mechanisms, such as increasing insulin secretion, improving insulin sensitivity, reducing glucose absorption from the gut, or decreasing glucose production by the liver. Oral hypoglycemic agents are typically prescribed when lifestyle modifications such as diet and exercise alone are insufficient to control blood sugar. The main product types of oral hypoglycemic agents are sulfonylureas, metformin, thiazolidinediones, alpha-glucosidase inhibitors, and immunotherapy. Sulfonylureas refer to a class of oral hypoglycemic agents that stimulate the pancreas to release more insulin by acting on beta cells, thereby helping lower blood glucose levels in individuals with type 2 diabetes. The various routes of administration include oral tablets, oral liquids, extended-release formulations, and combination therapy formulations. The multiple patient types include type 2 diabetes mellitus patients, pre-diabetic patients, obese or overweight patients, and patients with multiple comorbidities and are distributed through several channels such as hospital pharmacies, retail pharmacies, online pharmacies, and nursing homes and long-term care facilities. The different end users include hospitals and clinics.

What Is The Oral Hypoglycemic Agents Market Growth Forecast?

The oral hypoglycemic agents market size is expected to see steady growth in the next few years. It will grow to $75.62 billion in 2030 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to increasing lifestyle-related diabetes cases, rising demand in emerging economies, advancements in oral drug formulations, expansion of preventive diabetes care, growth of long-term diabetes management programs. Major trends in the forecast period include increasing adoption of combination oral therapies, growing use of metformin-based regimens, rising focus on early type 2 diabetes management, expansion of extended-release oral formulations, increasing demand for cost-effective diabetes drugs.

What Is The Driver Of The Oral Hypoglycemic Agents Market?

The rise in type 2 diabetes prevalence is expected to propel the growth of the oral hypoglycemic agents market going forward. Type 2 diabetes refers to a chronic metabolic disorder characterized by the body’s ineffective use of insulin, leading to elevated blood glucose levels. Type 2 diabetes is rising due to the increasing prevalence of sedentary lifestyles, which significantly reduce physical activity and contribute to obesity and insulin resistance. Oral hypoglycemic agents help manage type 2 diabetes by lowering blood glucose levels through various mechanisms, such as enhancing insulin sensitivity, stimulating insulin secretion, or reducing glucose absorption. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium-based non-profit organization, nearly 589 million adults aged 20–79 are living with diabetes worldwide, and this number is projected to rise significantly to 853 million by 2050. Therefore, the rising incidence of type 2 diabetes drives growth in the oral hypoglycemic agents industry.

Key Players In The Global Oral Hypoglycemic Agents Market

Major companies operating in the oral hypoglycemic agents market are Merck Sharp & Dohme Corp., AstraZeneca plc, Boehringer Ingelheim Ltd., Takeda Pharmaceuticals Limited, Bayer AG, Pfizer Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Huadong Medicine Co. Ltd., Wanbang Biopharmaceuticals Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Biocon Limited

Global Oral Hypoglycemic Agents Market Trends and Insights

Major companies operating in the oral hypoglycemic agents market are focusing on developing innovative products such as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) to improve glycemic control and reduce diabetes-related complications. Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are a class of oral medications that lower blood sugar by preventing the kidneys from reabsorbing glucose, causing excess glucose to be excreted in the urine, which helps improve glycemic control, reduce body weight, and lower the risk of heart and kidney complications in patients with type-2 diabetes. For instance, in June 2024, AstraZeneca plc, a UK-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for Farxiga (dapagliflozin), an oral SGLT2 inhibitor designed to support the treatment of paediatric type 2 diabetes in patients aged 10 years and older. The approval features once-daily oral dosing, demonstrated safety and efficacy in paediatric clinical trials and a first-in-class mechanism of action. Farxiga improves treatment accessibility, supports better long-term glycemic control and expands therapeutic options within the oral hypoglycemic landscape.

What Are Latest Mergers And Acquisitions In The Oral Hypoglycemic Agents Market?

In July 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche aims to strengthen its presence in the obesity and diabetes treatment market by expanding its pipeline of advanced incretin-based therapies. Carmot Therapeutics Inc. is a US-based company specializing in developing incretin-based therapies for obesity, diabetes, and related metabolic disorders.

What Defines the Oral Hypoglycemic Agents Market?

The oral hypoglycemic agents market consists of sales of DPP-4 inhibitors, alpha-glucosidase inhibitors, biguanides, and thiazolidinediones (TZDs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oral Hypoglycemic Agents Market Report 2026?

The oral hypoglycemic agents market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oral hypoglycemic agents industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.